Literature DB >> 7534797

An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.

R E Toes1, R Offringa, R J Blom, R M Brandt, A J van der Eb, C J Melief, W M Kast.   

Abstract

Mouse embryo cells (C57BL/6, H-2b) transformed by the E1A and E1B genes of adenovirus type 5 (Ad5E1 MEC) are highly immunogenic. Previously, CTL were cloned from mice immunized with Ad5E1 MEC. These CTL clones were capable of tumor eradication in nude mice, and were directed against the Ad5E1A-encoded decapeptide SGPSNTPPEI, presented by the H-2Db MHC molecule. We have now generated Ad5E1 MEC containing a mutated Ad5E1A-encoded epitope. The mutant Ad5E1 MEC induce a strong CTL response when injected into immunocompetent mice. CTL clones generated against mutant Ad5E1-transformed tumor cells recognize an Ad5E1B-encoded epitope (VNIRNCCYI) in the context of H-2Db. Because this epitope is also present on wild-type Ad5E1 MEC, it is concluded that Ad5E1-transformed tumor cells express at least two CTL epitopes. Interestingly, the lysis of Ad5E1 MEC by the Ad5E1B-specific, but not by the Ad5E1A-specific, CTL clones was strongly diminished by the action of the activated ras oncogene. CTL directed against the Ad5E1B-encoded epitope were, like Ad5E1A-specific CTL, able to eradicate large established Ad5E1-induced tumors in B6 nude mice, demonstrating that CTL activity directed against different CTL epitopes expressed by the same tumor can be exploited for immunotherapy of cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534797

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells.

Authors:  H Singh-Jasuja; N Hilf; H U Scherer; D Arnold-Schild; H G Rammensee; R E Toes; H Schild
Journal:  Cell Stress Chaperones       Date:  2000-11       Impact factor: 3.667

2.  PI31 is a modulator of proteasome formation and antigen processing.

Authors:  Dietmar M W Zaiss; Sybille Standera; Peter-M Kloetzel; Alice J A M Sijts
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

3.  IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye.

Authors:  Terry G Coursey; Peter W Chen; Jerry Y Niederkorn
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

4.  Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice.

Authors:  M K Song; S W Lee; Y S Suh; K J Lee; Y C Sung
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion.

Authors:  R E Toes; R C Hoeben; E I van der Voort; M E Ressing; A J van der Eb; C J Melief; R Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

6.  Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

Authors:  R E Toes; R Offringa; R J Blom; C J Melief; W M Kast
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

7.  Abrogating TNF-α expression prevents bystander destruction of normal tissues during iNOS-mediated elimination of intraocular tumors.

Authors:  Terry G Coursey; Peter W Chen; Jerry Y Niederkorn
Journal:  Cancer Res       Date:  2011-02-09       Impact factor: 12.701

8.  Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.

Authors:  Ann J Ligocki; Joseph R Brown; Jerry Y Niederkorn
Journal:  J Leukoc Biol       Date:  2015-11-17       Impact factor: 4.962

9.  Enhancement of cytotoxic T-lymphocyte response in aged mice by a novel treatment with recombinant AdIL-12 and wild-type adenovirus in rapid succession.

Authors:  Jian Chen; John Wang; Jun Li; Qi Wu; Fei Chu Lim; Pingar Yang; Hui-Chen Hsu; David T Curiel; John D Mountz
Journal:  Mol Ther       Date:  2008-06-10       Impact factor: 11.454

10.  CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages.

Authors:  Dru S Dace; Peter W Chen; Jerry Y Niederkorn
Journal:  Immunology       Date:  2007-10-17       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.